Last reviewed · How we verify

Abliva AB — Portfolio Competitive Intelligence Brief

Abliva AB pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Midazolam injection Midazolam injection marketed Benzodiazepine [EPC]

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Abbott · 1 shared drug class
  3. Generic (originally Roche) · 1 shared drug class
  4. Generic (originally Wyeth/Pfizer) · 1 shared drug class
  5. Lundbeck Pharms Llc · 1 shared drug class
  6. Mallinckrodt · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Abliva AB:

Cite this brief

Drug Landscape (2026). Abliva AB — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/abliva-ab. Accessed 2026-05-13.

Related